

Referencias bibliográficas

1. Hurst JW, Morris DC, Alexander RW. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. *Clin Cardiol* 1999;22(6):385-90.
2. Raphael C, Briscoe C, Davies J, et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. *Heart* 2007;93(4):476-82.
3. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. *Circulation* 1993;87(6 Suppl):VI5-16.
4. Pinski SL, Yao Q, Epstein AE, et al. Determinants of outcome in patients with sustained ventricular tachyarrhythmias: the antiarrhythmics versus implantable defibrillators (AVID) study registry. *Am Heart J* 2000;139(5):804-13.
5. Podrid PJ, Fogel RI, Fuchs TT. Ventricular arrhythmia in congestive heart failure. *Am J Cardiol* 1992;69(18):82G-95G; discussion G-6G.
6. le Heuzey JY, Aliot E. [Implantable cardioverter defibrillator: an update]. *Med Sci (Paris)* 2007;23(1):88-92.
7. Sorbera CA, Cusack EJ. Indications for implantable cardioverter defibrillator therapy. *Heart Dis* 2002;4(3):166-70.
8. Gasparini M, Bocchiardo M, Lunati M, et al. Comparison of 1-year effects of left ventricular and biventricular pacing in patients with heart failure who have ventricular arrhythmias and left bundle-branch block: the Bi vs Left Ventricular Pacing: an International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias (BELIEVE) multicenter prospective randomized pilot study. *Am Heart J* 2006;152(1):155 e1-7.
9. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. *J Cardiovasc Electrophysiol* 2004;15(9):1002-9.
10. Delise P, Sciarra L. [The problem of sudden death in heart failure]. *Ital Heart J* 2005;6 Suppl 1:24S-33S.
11. Rosanio S, Schwarz ER, Vitarelli A, et al. Sudden death prophylaxis in heart failure. *Int J Cardiol* 2007;119(3):291-6.
12. Yeim S, Bordachar P, Reuter S, et al. Predictors of a positive response to biventricular pacing in patients with severe heart failure and ventricular conduction delay. *Pacing Clin Electrophysiol* 2007;30(8):970-5.
13. Farwell D, Patel NR, Hall A, Ralph S, Sulke AN. How many people with heart failure are appropriate for biventricular resynchronization? *Eur Heart J* 2000;21(15):1246-50.
14. Alonso C, Leclercq C, Victor F, et al. Electrocardiographic predictive factors of long-term clinical improvement with multisite biventricular pacing in advanced heart failure. *Am J Cardiol* 1999;84(12):1417-21.
15. Yu CM, Chan YS, Zhang Q, et al. Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. *J Am Coll Cardiol* 2006;48(11):2251-7.
16. Yuan XP, White JA, Yee R, Drangova M. Tissue Doppler Imaging of Mitral Annular Motion Is an Effective Surrogate of Left Ventricular Dyssynchrony and Predicts Response to Cardiac Resynchronization Therapy. *J Am Soc Echocardiogr* 2007.
17. Phillips KP, Harberts DB, Johnston LP, O'Donnell D. Left ventricular resynchronization predicted by individual performance of right and left univentricular pacing: a study on the impact of sequential biventricular pacing on ventricular dyssynchrony. *Heart Rhythm* 2007;4(2):147-53.
18. Zamorano J, Perez de Isla L, Roque C, Khanhderia B. The role of echocardiography in the assessment of mechanical dyssynchrony and its importance in predicting response to prognosis after cardiac resynchronization therapy. *J Am Soc Echocardiogr* 2007;20(1):91-9.
19. Yildirim A, Soyulu O, Dagdeviren B, Zor U, Tezel T. Correlation between Doppler derived dP/dt and left ventricular asynchrony in patients with dilated cardiomyopathy: A combined study using strain rate imaging and conventional Doppler echocardiography. *Echocardiography* 2007;24(5):508-14.
20. Waggoner AD, Agler DA, Adams DB. Cardiac resynchronization therapy and the emerging role of echocardiography (part 1): indications and results from current studies. *J Am Soc Echocardiogr* 2007;20(1):70-5.
21. Vitarelli A, Franciosa P, Rosanio S. Tissue Doppler Imaging in the assessment of selection and response from cardiac resynchronization therapy. *Eur J Echocardiogr* 2007.

22. Van de Veire N, Bleeker G, De Sutter J, et al. Tissue synchronization imaging accurately measures left ventricular dyssynchrony and predicts response to cardiac resynchronization therapy. *Heart* 2007.
23. Trimble MA, Borges-Neto S, Smallheiser S, et al. Evaluation of left ventricular mechanical dyssynchrony as determined by phase analysis of ECG-gated SPECT myocardial perfusion imaging in patients with left ventricular dysfunction and conduction disturbances. *J Nucl Cardiol* 2007;14(3):298-307.
24. Mule JD, Martinelli F. Assessment of dyssynchrony in patients with severe heart failure by nuclear imaging: paradise lost and regained or lost and gone forever? *Ital Heart J* 2005;6(2):96-105.
25. O'Connell JW, Schreck C, Moles M, et al. A unique method by which to quantitate synchrony with equilibrium radionuclide angiography. *J Nucl Cardiol* 2005;12(4):441-50.
26. Somsen GA, Verberne HJ, Burri H, Ratib O, Righetti A. Ventricular mechanical dyssynchrony and resynchronization therapy in heart failure: a new indication for Fourier analysis of gated blood-pool radionuclide ventriculography. *Nucl Med Commun* 2006;27(2):105-12.
27. Agler DA, Adams DB, Waggoner AD. Cardiac resynchronization therapy and the emerging role of echocardiography (part 2): the comprehensive examination. *J Am Soc Echocardiogr* 2007;20(1):76-90.
28. Yu CM, Zhang Q, Yip GW, et al. Are left ventricular diastolic function and diastolic asynchrony important determinants of response to cardiac resynchronization therapy? *Am J Cardiol* 2006;98(8):1083-7.
29. Westenberg JJ, Lamb HJ, van der Geest RJ, et al. Assessment of left ventricular dyssynchrony in patients with conduction delay and idiopathic dilated cardiomyopathy: head-to-head comparison between tissue doppler imaging and velocity-encoded magnetic resonance imaging. *J Am Coll Cardiol* 2006;47(10):2042-8.
30. Khoshnevis GR, Massumi A. Ventricular arrhythmias in congestive heart failure: clinical significance and management. *Tex Heart Inst J* 1999;26(1):42-59.
31. Budde T. AICD treatment in 2004—state of the art. *Eur J Med Res* 2006;11(10):432-8.
32. Stevenson LW. Implantable cardioverter-defibrillators for primary prevention of sudden death in heart failure: are there enough bangs for the bucks? *Circulation* 2006;114(2):101-3.
33. Field ME, Sweeney MO. Socio-economic analysis of cardiac resynchronization therapy. *J Interv Card Electrophysiol* 2006;17(3):225-36.
34. Zareba W, Piotrowicz K, McNitt S, Moss AJ. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). *Am J Cardiol* 2005;95(12):1487-91.
35. Chonchol M, Goldenberg I, Moss AJ, McNitt S, Cheung AK. Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. *Am J Nephrol* 2007;27(1):7-14.
36. Moss AJ. Update on MADIT: the Multicenter Automatic Defibrillator Implantation Trial. The long QT interval syndrome. *Am J Cardiol* 1997;79(6A):16-9.
37. Mower MM. Overview of implantable cardioverter-defibrillator in reducing total mortality in the high-risk coronary patient. *Md Med J* 1997;46(2):75-8.
38. Mushlin AI, Zwanziger J, Gajary E, Andrews M, Marron R. Approach to cost-effectiveness assessment in the MADIT trial. Multicenter Automatic Defibrillator Implantation Trial. *Am J Cardiol* 1997;80(5B):33F-41F.
39. Nisam S. Do MADIT results apply only to “MADIT patients”? Multicenter Automatic Defibrillator Implantation Trial. *Am J Cardiol* 1997;79(6A):27-30.
40. Nisam S, Adragao P. Clinical implications of the “Multicenter Automatic Defibrillator Implantation Trial” (MADIT). *Rev Port Cardiol* 1997;16(4):359-64, 1.
41. Saksena S. On MADIT and future clinical trials for prevention of sudden cardiac death. Multicenter Automatic Defibrillator Implantation Trial. *J Interv Card Electrophysiol* 1997;1(2):91-3.
42. Saksena S, Giorgberidze II. The Multicenter Automatic Defibrillator Implantation Trial. *J Cardiovasc Pharmacol Ther* 1997;2(3):229-38.
43. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomised controlled trials. *Jama* 2004;292(23):2874-9.
44. Matsuda N. [Implantable cardioverter-defibrillator in patients with chronic heart failure]. *Nippon Rinsho* 2006;64(5):949-54.
45. Goldberger Z, Lampert R. Implantable cardioverter-defibrillators: expanding indications and technologies. *Jama* 2006;295(7):809-18.
46. Turitto G, El-Sherif N. Cardiac resynchronization therapy: a review of proarrhythmic and antiarrhythmic mechanisms. *Pacing Clin Electrophysiol* 2007;30(1):115-22.
47. Pieragnoli P, Ricciardi G, Colella A, et al. Is implantable defibrillator indicated in all patients on cardiac resynchronization therapy? *Minerva Cardioangiol* 2006;54(6):735-41.

48. Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. *Eur Heart J* 2007;28(1):42-51.
49. Ypenburg C, van Erven L, Bleeker GB, et al. Benefit of combined resynchronization and defibrillator therapy in heart failure patients with and without ventricular arrhythmias. *J Am Coll Cardiol* 2006;48(3):464-70.
50. Voigt A, Barrington W, Ngwu O, Jain S, Saba S. Biventricular pacing reduces ventricular arrhythmic burden and defibrillator therapies in patients with heart failure. *Clin Cardiol* 2006;29(2):74-7.
51. Pires LA, Abraham WT, Young JB, Johnson KM. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials. *Am Heart J* 2006;151(4):837-43.
52. Schaumann A, Tack C, Kuck KH. [Sudden cardiac death, ICD and resynchronization therapy]. *Herz* 2006;31(9):857-63.
53. Stellbrink C. [Cardiac resynchronization therapy-always with ICD?]. *Herz* 2005;30(7):596-600.
54. Achilli A, Turreni F, Gasparini M, et al. Efficacy of cardiac resynchronization therapy in very old patients: the Insync/Insync ICD Italian Registry. *Europace* 2007.
55. Leclercq C. [Cardiac resynchronisation therapy: what kind of equipment to use?]. *Ann Cardiol Angeiol (Paris)* 2005;54(1):12-6.
56. Auricchio A, Metra M, Gasparini M, et al. Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. *Am J Cardiol* 2007;99(2):232-8.
57. Rivera DA, Bristow MR. Cardiac resynchronization—a heart failure perspective. *Ann Noninvasive Electrocardiol* 2005;10(4 Suppl):16-23.
58. Feldman AM, de Lissoyoy G, Bristow MR, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. *J Am Coll Cardiol* 2005;46(12):2311-21.
59. Carson P, Anand I, O'Connor C, et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. *J Am Coll Cardiol* 2005;46(12):2329-34.
60. Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. *Eur Heart J* 2005;26(24):2681-8.
61. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CARDiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. *Eur Heart J* 2006;27(16):1928-32.
62. Israel CW, Butter C. [Indication for cardiac resynchronization therapy: Consensus 2005]. *Herzschrittmacherther Elektrophysiol* 2006;17 Suppl 1:180-6.
63. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, Boersma E, Simoons M, Jordaens LJ. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. *Eur Heart J* 2006.
64. Aaronaes M, Atar D, Bonarjee V, et al. [Treatment of congestive heart failure]. *Tidsskr Nor Laegeforen* 2007;127(2):174-7.
65. Czuriga I. [Chronic heart failure—the epidemic of the 21st century]. *Orv Hetil* 2005;146(20 Suppl 2):1075-87.
66. Amara W, Mazouz S, Sergeant J. [How to carry out the indications of cardiac resynchronization therapy in practice?]. *Ann Cardiol Angeiol (Paris)* 2006;55(6):306-14.
67. Patwala AY, Wright DJ. Device based treatment of heart failure. *Postgrad Med J* 2005;81(955):286-91.
68. Linde C, Gold M, Abraham WT, Daubert JC. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure—the REsynchronization reverses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. *Am Heart J* 2006;151(2):288-94.
69. Leclercq C, Crocq C, Mabo P, Daubert C. [Role of cardiac resynchronisation in the treatment of cardiac failure]. *Arch Mal Coeur Vaiss* 2004;97(11):1116-21.